Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Adaptimmune Therapeutics PLC (ADAP)
|
Add to portfolio |
|
|
|
| Price: |
$5.07
| | Metrics |
| OS: |
1.36
|
B
| |
|
|
| Market cap: |
$6.88
|
B
| |
-60
|
% ROIC
|
|
|
|
| |
|
|
|
|
|
| | | |
| | | | | |
| TTM Valuation | | | |
|
|
|
| |
|
|
|
|
|
| |
|
|
| EPS |
($0.09)
| |
|
|
|
BVPS
|
$0.09
| |
54.32
|
x P/B
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 27.1 | 6.1 | 4.0 | 1.1 | 59.5 | 37.8 | 14.2 | 14.5 |
| Revenue growth | 341.5% | 55.4% | 252.8% | -98.1% | 57.3% | 166.5% | -2.0% | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 27.1 | 6.1 | 4.0 | 1.1 | 59.5 | 37.8 | 14.2 | 14.5 |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Selling, general and administrative | | | | | | | | 0.0 |
| Research and development | 127.7 | 111.1 | 91.6 | 97.5 | 98.3 | 87.4 | 63.8 | |
| General and administrative | 63.4 | 57.3 | 45.8 | 43.4 | 43.6 | 31.1 | 23.2 | 0.0 |
| EBITA | -163.2 | -161.3 | -132.4 | -138.9 | -81.7 | -80.3 | -72.6 | -43.1 |
| EBITA margin | -601.0% | -2623.3% | -3346.1% | -12382.5% | -137.4% | -212.2% | -511.6% | -297.6% |
| Amortization of intangibles | 0.8 | 0.9 | 1.0 | 0.8 | 0.6 | 0.4 | 0.2 | |
| EBIT | -164.0 | -162.2 | -133.4 | -139.8 | -82.4 | -80.7 | -72.8 | -43.1 |
| EBIT margin | -604.0% | -2638.6% | -3370.5% | -12457.2% | -138.4% | -213.2% | -512.7% | -297.6% |
| Pre-tax income | -163.0 | -157.3 | -129.9 | -136.9 | -95.0 | -69.7 | -70.7 | -39.4 |
| Income taxes | 2.5 | 0.8 | 0.2 | 0.2 | 0.5 | 0.5 | 0.9 | 0.1 |
| Net income | -165.5 | -158.1 | -130.1 | -137.2 | -95.5 | -70.1 | -71.6 | -39.5 |
| Net margin | -609.5% | -2571.0% | -3286.8% | -12225.0% | -160.5% | -185.4% | -504.1% | -272.7% |
| |
| Diluted EPS | ($0.17) | ($0.17) | ($0.15) | ($0.22) | ($0.16) | ($0.13) | ($0.17) | |
| Shares outstanding (diluted) | 967.2 | 934.8 | 854.8 | 629.8 | 584.3 | 527.6 | 424.7 | |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|